Lotus Eye Hospital and Institute Ltd Stock Price Today (NSE: LOTUSEYE)
Fundamental Score
Lotus Eye Hospital and Institute Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lotus Eye Hospital and Institute Ltd share price today is ₹102.51, up +0.66% on NSE/BSE as of 16 April 2026. Lotus Eye Hospital and Institute Ltd (LOTUSEYE) is a Small-cap company in the Hospital sector with a market capitalisation of ₹215.03 (Cr). The 52-week high for LOTUSEYE share price is ₹147.00 and the 52-week low is ₹64.50. At a P/E ratio of 320.93x, LOTUSEYE is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 1.22% and a debt-to-equity ratio of 0.08.
Lotus Eye Hospital and Institute Ltd Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued micro-cap eye care play with poor profitability and high liquidity risk; avoid until fundamentals improve.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Lotus Eye Hospital decided not to proceed with the voluntary delisting from NSE. Sangeetha Sundaramoorthy acquired a 6.87% stake from Kavetha Sundaramoorthy for approximately ₹100 million. 🧠 CORE STORY (THE REAL GAME): Micro-cap eye care roll-up. Market is pricing in continued, albeit slow, growth and potential value unlocking through strategic initiatives like delisting (now off the table) or acquisitions. The key is whether they can scale operations efficiently. 🔥 WHAT IS DRIVING THE STOCK: 1. **Stake Acquisition:** Sangeetha Sundaramoorthy's increased stake signals confidence, but also raises questions about promoter dominance. 2. **Delisting Uncertainty:** The initial delisting proposal and subsequent withdrawal created volatility, highlighting the stock's sensitivity to corporate actions. 3. **Modest Growth:** Q3 FY26 revenue increased 10.59% YoY to ₹13.79Cr, while net profit fell 8.33% to ₹0.26Cr, indicating mixed performance. ⚖️ BULL vs BEAR: Bull: Consolidation in the eye care market, potential for improved operational efficiencies, and strategic acquisitions could drive growth. Promoter's increased stake could lead to better governance. Bear: Micro-cap illiquidity. High P/E of 320.93x vs. industry P/E of 52.84x signals overvaluation. Declining promoter holding over the last 3 years is concerning. Low ROE of 1.22% and ROCE of 2.99% indicate poor profitability. Risk of continued underperformance given poor sales growth of 4.09% over the past five years. 💣 WHAT MARKET IS PRICING: The market is pricing in a turnaround story, expecting Lotus Eye to significantly improve profitability and growth. This expectation is fragile and vulnerable to earnings disappointments. 🎯 BOTTOM LINE: Hope trade on a micro-cap with stretched valuation and questionable profitability. Liquidity risk is high. Avoid.
- Stake acquisition by promoter
- Delisting proposal (now withdrawn) caused volatility
- Modest revenue growth but declining profits
- Successful acquisitions
- Significant improvement in profitability
- Favorable regulatory changes in the healthcare sector
- Micro-cap illiquidity
- High P/E relative to industry
- Low ROE and ROCE
- Decreasing promoter holding over the last 3 years
FII: 0.0% (Δ -0.01%) indicates lack of institutional interest. Promoter increased stake by 0.25%, a mildly positive signal.
India's hospital sector is expected to grow at a CAGR of up to 12% over the next 3-5 years, a potential tailwind.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order on March 4, 2026. Specifics of the order not found after live search.
No: Free Cash Flow 5Y: ₹1.67 Cr.
Next 3-6 months hinge on execution. If they can't demonstrate improved profitability, expect a correction. Key is to monitor cash flow and ROE.
Primary Thesis Risk
Inability to scale operations and improve profitability will lead to significant downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Lotus Eye Hospital and Institute Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Lotus Eye Hospital and Institute Share Price: A Financial Analysis
The Indian healthcare sector is experiencing robust growth, fueled by an aging population and increasing healthcare awareness. This analysis examines the financial standing of Lotus Eye Hospital and Institute Ltd, focusing specifically on the "Lotus Eye Hospital and Institute share price" and related financial metrics. Currently, the share price stands at ₹122.18. A key metric to consider is the Price-to-Earnings (PE) ratio, which at 320.93, suggests that the market has very high expectations for future earnings growth. This elevated PE ratio warrants careful scrutiny, especially when considering the company's Return on Capital Employed (ROCE).
The ROCE of 2.99% is notably low. ROCE measures how efficiently a company uses its capital to generate profits. A low ROCE indicates that Lotus Eye Hospital and Institute Ltd is not generating significant returns relative to the capital it has invested. This directly impacts the company's "moat" or competitive advantage. A stronger ROCE would signify a more robust ability to fend off competition and generate sustainable profits. Comparing Lotus Eye Hospital and Institute Ltd with peers like
Nephro Care India Limited, one might delve into the qualitative aspects like management quality and strategic decision-making to understand the disparity in financial performance. Observing leadership effectiveness and strategic foresight can offer clues as to why Nephro Care India Limited is outperforming relative to the sector.The contrast in PE ratios and ROCE between Lotus Eye Hospital and Institute Ltd and its peers suggests the need for further investigation. Factors to consider include the specific services offered (e.g., specialization in a high-margin segment of eye care), the geographic footprint of the hospital network (e.g., presence in high-growth regions), and the cost structure (e.g., economies of scale in procurement). The sustainability of Lotus Eye Hospital and Institute Ltd’s earnings growth, given its current ROCE, is a key area to monitor. Further financial statement analysis is needed to get a comprehensive view of the company’s outlook.
This analysis is based on publicly available data and is intended for informational purposes only. It forms part of a larger, 80-parameter fundamental audit process that has been verified by Sweta Mishra. It is essential to conduct thorough due diligence before making any investment decisions. This is not a recommendation to buy or sell shares of Lotus Eye Hospital and Institute Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lotus Eye Hospital and Institute Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LOTUSEYE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (20.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.99%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 320.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (4.09% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-12.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.83% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lotus Eye Hospital and Institute Ltd Financial Statements
Comprehensive financial data for Lotus Eye Hospital and Institute Ltd including income statement, balance sheet and cash flow
About LOTUSEYE (Lotus Eye Hospital and Institute Ltd)
Lotus Eye Hospital and Institute Ltd is a beacon of ophthalmic excellence, dedicated to preserving and enhancing vision through cutting-edge technology and compassionate care. Our ...state-of-the-art facilities house a comprehensive range of diagnostic and surgical equipment, enabling our team of highly skilled ophthalmologists to provide tailored treatments for a wide spectrum of eye conditions. From the subtle nuances of refractive errors to the complexities of retinal diseases, we approach each patient with a personalized strategy, prioritizing precision and optimal outcomes. We strive to create a comfortable and supportive environment, ensuring that every individual feels informed, empowered, and confident in their journey towards improved vision. Our commitment extends beyond clinical expertise to encompass a deep understanding of the emotional and psychological impact of vision impairment, fostering a holistic approach to eye care. Our hospital is renowned for its pioneering advancements in refractive surgery, offering a suite of sophisticated procedures designed to correct vision without the need for glasses or contact lenses. We utilize advanced techniques such as Femto LASIK, Contoura Vision, and ReLEx SMILE, tailoring each procedure to the unique characteristics of the patient's eye. In addition to refractive surgery, we specialize in the diagnosis and treatment of cataracts, glaucoma, and other vision-threatening conditions. Our surgeons are proficient in performing minimally invasive cataract surgery using advanced phacoemulsification and femtosecond laser technology. We provide comprehensive glaucoma management, utilizing the latest diagnostic tools and treatment modalities to preserve visual function and prevent further damage. Furthermore, Lotus Eye Hospital and Institute Ltd is committed to providing specialized care for children with eye disorders. Our pediatric ophthalmologists possess expertise in diagnosing and treating conditions such as strabismus (squint), amblyopia (lazy eye), and congenital cataracts. We understand the unique challenges of pediatric eye care and create a welcoming and child-friendly environment to ensure that young patients feel comfortable and at ease. Our institute is also dedicated to research and education, contributing to the advancement of ophthalmic knowledge and training the next generation of eye care professionals. We aim to be a center of excellence, continuously innovating and improving our services to provide the highest quality eye care to the community.
Company Details
Key Leadership
Corporate Events
LOTUSEYE Share Price: Frequently Asked Questions
What is the current share price of Lotus Eye Hospital and Institute Ltd (LOTUSEYE)?
As of 16 Apr 2026, 11:00 am IST, Lotus Eye Hospital and Institute Ltd share price is ₹102.51. The LOTUSEYE stock has a market capitalisation of ₹215.03 (Cr) on NSE/BSE.
Is LOTUSEYE share price Overvalued or Undervalued?
LOTUSEYE share price is currently trading at a P/E ratio of 320.93x, compared to the industry average of 52.84x. Based on this relative valuation, the Lotus Eye Hospital and Institute Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of LOTUSEYE share price?
The 52-week high of LOTUSEYE share price is ₹147.00 and the 52-week low is ₹64.50. These values are updated daily from NSE/BSE price data.
What factors affect the Lotus Eye Hospital and Institute Ltd share price?
Key factors influencing LOTUSEYE share price include quarterly earnings growth (Sales Growth: 1.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lotus Eye Hospital and Institute Ltd a good stock for long-term investment?
Lotus Eye Hospital and Institute Ltd shows a 5-year Profit Growth of -12.83% and an ROE of 1.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.08 before investing in LOTUSEYE shares.
How does Lotus Eye Hospital and Institute Ltd compare with its industry peers?
Lotus Eye Hospital and Institute Ltd competes with major peers in the Hospital. Investors should compare LOTUSEYE share price P/E of 320.93x and ROE of 1.22% against the industry averages to determine competitive standing.
What is the P/E ratio of LOTUSEYE and what does it mean?
LOTUSEYE share price has a P/E ratio of 320.93x compared to the industry average of 52.84x. Investors pay ₹321 for every ₹1 of annual earnings.
How is LOTUSEYE performing according to Bull Run's analysis?
LOTUSEYE has a Bull Run fundamental score of 22/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LOTUSEYE belong to?
LOTUSEYE operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lotus Eye Hospital and Institute Ltd share price.
What is Return on Equity (ROE) and why is it important for LOTUSEYE?
LOTUSEYE has an ROE of 1.22%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Lotus Eye Hospital and Institute Ltd generates profits from shareholders capital.
How is LOTUSEYE debt-to-equity ratio and what does it indicate?
LOTUSEYE has a debt-to-equity ratio of 0.08, which indicates conservative financing with low financial risk.
What is LOTUSEYE dividend yield and is it a good dividend stock?
LOTUSEYE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Lotus Eye Hospital and Institute Ltd shares.
How has LOTUSEYE share price grown over the past 5 years?
LOTUSEYE has achieved 5-year growth rates of: Sales Growth 4.09%, Profit Growth -12.83%, and EPS Growth -12.83%.
What is the promoter holding in LOTUSEYE and why does it matter?
Promoters hold 40.64% of LOTUSEYE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Lotus Eye Hospital and Institute Ltd.
What is LOTUSEYE market capitalisation category?
LOTUSEYE has a market capitalisation of ₹215 crores, placing it in the Small-cap category.
How volatile is LOTUSEYE stock?
LOTUSEYE has a beta of N/A. A beta > 1 suggests the Lotus Eye Hospital and Institute Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LOTUSEYE operating profit margin trend?
LOTUSEYE has a 5-year average Operating Profit Margin (OPM) of 12.69%, indicating the company's operational efficiency.
How is LOTUSEYE quarterly performance?
Recent quarterly performance shows Lotus Eye Hospital and Institute Ltd YoY Sales Growth of 1.01% and YoY Profit Growth of 20.00%.
What is the institutional holding pattern in LOTUSEYE?
LOTUSEYE has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the Lotus Eye Hospital and Institute Ltd stock.